MDGL Stock Analysis: Buy, Sell, or Hold?
MDGL - Madrigal Pharmaceuticals, Inc. Common Stock
$467.32
-25.79 (-5.23%)
▼
5d:
-14.18%
30d:
-9.15%
90d:
-9.68%
WAIT
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Smart Money Accumulation
None View Scanner →
Strength: 5.6/10
Get Alerted When MDGL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: MDGL is down 14.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: MDGL is down 14.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$433.66
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$269.27
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: MDGL is currently trading at $467.32, which is considered oversold relative to its 30-day fair value range of $517.49 to $551.17. From a valuation perspective, the stock is trading at a discount (Forward PE: 39.8) compared to its historical average (100.0). Remarkably, the market is currently pricing in an annual earnings decline of 26.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, MDGL is in a uptrend. Immediate support is located at $447.01, while resistance sits at $566.18. Short-term momentum is weak, with the stock down 5.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $680.00 (+37.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MDGL is in a uptrend. Immediate support is located at $447.01, while resistance sits at $566.18. Short-term momentum is weak, with the stock down 5.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $680.00 (+37.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$517.49 -
$551.17
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
Protect Your Profits
Holding MDGL? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.2%)
- BULLISH: Trading 37.9% below Wall St target ($680.00)
- WARNING: Recommendation downgraded due to -14.2% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$517.49 -
$551.17
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$447.01
Resistance Level
$566.18
Current Trend
Uptrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
39.83
Wall Street Target
$680.00
(+37.9%)
Revenue Growth (YoY)
126.8%
Profit Margin
-27.3%
Valuation Discount vs History
-26.4% cheaper
PE vs Historical
39.8 vs 100.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-26.4%
(market-implied from PE analysis)
1-Year Target
$443.80
(-10%)
2-Year Target
$399.42
(-19%)
3-Year Target
$359.48
(-27%)
3-Yr Target (if PE normalizes)
(PE: 40→100)
$902.50
(+83%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 39.8 to 100.0
Stabilization Target:
$1238.00
(+151.1%)
PE Expansion Potential:
+151.1%
Share & Embed Analysis
Last updated: August 02, 2026 5:44 PM ET
Data refreshes hourly during market hours. Next update: 6:44 PM
Data refreshes hourly during market hours. Next update: 6:44 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MDGL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Mardi Dier
SELL
1982 shares
2026-03-06
Carole Huntsman
SELL
419 shares
2026-03-06
William John Sibold
SELL
1663 shares
2026-03-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 53 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$282 | 54 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$33 | 60 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$105 | 56 HOLD |
Advanced MDGL Option Strategies
Professional options setups generated by AI based on today's MDGL price and gamma walls.
